UBR2 and neoplasm: Consistent with their effect in vitro, these neutralizing antibodies blocked tumor-induced catabolic response measured by activation of p38 MAPK, upregulation of atrogin1 and UBR2, increase of autophagy marker LC3-II and loss of MHC in tibialis anterior (TA, Fig. 2c).